Abstract
The arrival of several new agents--cabazitaxel, abiraterone acetate, enzalutamide, and radium-223--is changing the treatment options and management of patients with metastatic castration-resistant prostate cancer (mCRPC). Many other novel agents are also being investigated. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. This review article is a summary of a European Treatment Practices Meeting, which was convened to discuss these latest data on novel agents and current treatment strategies in the mCRPC setting.
Keywords:
Abiraterone acetate; Cabazitaxel; Docetaxel; Enzalutamide; Metastatic castration-resistant; Prostate cancer; Treatment.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Abiraterone Acetate
-
Androgen Antagonists / administration & dosage*
-
Androstadienes / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Benzamides
-
Clinical Trials as Topic
-
Docetaxel
-
Humans
-
Male
-
Neoplasm Metastasis / drug therapy*
-
Neoplasm Metastasis / pathology
-
Nitriles
-
Phenylthiohydantoin / administration & dosage
-
Phenylthiohydantoin / analogs & derivatives
-
Prostatic Neoplasms, Castration-Resistant / drug therapy*
-
Prostatic Neoplasms, Castration-Resistant / pathology
-
Taxoids / administration & dosage
Substances
-
Androgen Antagonists
-
Androstadienes
-
Benzamides
-
Nitriles
-
Taxoids
-
Docetaxel
-
Phenylthiohydantoin
-
cabazitaxel
-
enzalutamide
-
Abiraterone Acetate